Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

Tanios Bekaii-Saab, MD
Published: Saturday, Apr 23, 2016



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses 2 new agents, regorafenib and TAS-102, for the treatment of patients with colorectal cancer.

Phase III studies have shown that both agents improved outcomes when compared with placebo in refractory settings, Bekaii-Saab explains.

Currently, there is only sequencing data for patients to receive regorafenib first followed by TAS-102; therefore, that is how the agents are used together. However, Bekaii-Saab emphasizes that there are certain instances where one therapy should be used versus the other.

<<< View more from the 2016 School of Gastrointestinal Oncology



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses 2 new agents, regorafenib and TAS-102, for the treatment of patients with colorectal cancer.

Phase III studies have shown that both agents improved outcomes when compared with placebo in refractory settings, Bekaii-Saab explains.

Currently, there is only sequencing data for patients to receive regorafenib first followed by TAS-102; therefore, that is how the agents are used together. However, Bekaii-Saab emphasizes that there are certain instances where one therapy should be used versus the other.

<<< View more from the 2016 School of Gastrointestinal Oncology


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x